Check out Safety Emporium for your N95, N99, and face shield needs.
Previous by Date: Subject: Re: [DCHAS-L] Face shields and masks Date: Thursday, September 3, 2020 at 9:56:21 PM Author: ILPI Support <info**At_Symbol_Here**ILPI.COM>
From: DCHAS Membership Chair <membership**At_Symbol_Here**DCHAS.ORG>
Subject: [DCHAS-L] EPA HERA Program Update: September 2020 Pharmacokinetic Modeling for Chloroprene
Date: Fri, 4 Sep 2020 07:32:38 -0400
Reply-To: ACS Division of Chemical Health and Safety <DCHAS-L**At_Symbol_Here**Princeton.EDU>
Message-ID: BB4E77BA-7595-42A1-AA06-5CBFF0720BB8**At_Symbol_Here**dchas.org
HERA Program Update: September 2020
HERA Program Update: September 2020
Update: External Peer Review Meeting Announced - Report on Physiologically Based Pharmacokinetic Modeling for Chloroprene and a Supplemental Analysis of Metabolite Clearance
Notice: In July 2020, EPA's Integrated Risk Information System (IRIS) Program announced a 30-day public comment period associated with the report titled "Incorporation of in vitro metabolism data in a physiologically based pharmacokinetic (PBPK) model for chloroprene" developed by Ramboll, a contractor to Denka Performance Elastomer, LLC (DPE), and an "Uncertainty analysis of in vitro metabolic parameters and of in vitro to in vivo extrapolation used in a PBPK model for chloroprene" developed by EPA. These documents are undergoing independent external scientific peer review managed by Versar, an EPA contractor.
Versar is announcing a virtual Public Meeting will be held on October 5 and 6, 2020, from 9:00 a.m. to 5:00 p.m. (EDT).Interested attendees must register online to receive the webcast meeting link and audio teleconference information for participation.
To attend the peer review virtual meeting, register no later than October 1, 2020 by visiting the peer review meeting website or the meeting registration page. There will be a limited amount of time for oral statements from the public near the beginning of the peer review meeting on the first day. If you wish to make an oral statement during the meeting, you must notify Versar of your request to speak no later than October 1, 2020. Versar will notify speakers of specific time limits for their oral statements. Versar will accept requests to make oral statements on a first-come, first-served basis, and may limit the amount of time for each speaker as well as the number of speakers due to time constraints.
Questions regarding the peer review should be submitted to Versar, Inc. by email: chloroprenePBPK**At_Symbol_Here**versar.com (Subject line: Chloroprene PBPK Peer Review); or by phone (301) 304-3121 (ask for Tracey Cowen).
The content of this page reflects the personal opinion(s) of the author(s) only, not the American Chemical Society, ILPI, Safety Emporium, or any other party. Use of any information on this page is at the reader's own risk. Unauthorized reproduction of these materials is prohibited. Send questions/comments about the archive to secretary@dchas.org. The maintenance and hosting of the DCHAS-L archive is provided through the generous support of Safety Emporium.